Basal Ganglia Pathophysiology
161 – 170 of 197
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
- Contribution to journal › Article
-
Mark
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
- Contribution to journal › Article
-
Mark
Mechanisms of L-DOPA-induced dyskinesia in Parkinson´s disease: What do animal models tell us?
(2006) p.351-360
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Dyskinesia and neural grafting in Parkinson's disease
(2006) p.184-224
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2005
-
Mark
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
- Contribution to journal › Article
-
Mark
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
- Contribution to journal › Article
-
Mark
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
- Contribution to journal › Article
-
Mark
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
- Contribution to journal › Article
-
Mark
Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective.
- Contribution to journal › Article
-
Mark
Orexin loss in Huntington's disease.
- Contribution to journal › Article
